A father’s death from pancreatic cancer sparks a decades-long hunt for a better answer, and it leads to one surprising place: the cell walls of baker’s yeast. We’re joined by Mike Catto, a researcher and biotech founder, to unpack beta-glucan and why the specific 1-3/1-6 linkage he works with matters for immune modulation and cancer immunotherapy.

We walk through Mike’s path from early biopolymer work to acquiring failed injectable beta-glucan patents, rebuilding the process, and pushing through an expensive FDA clinical-trial journey. He shares why major cancer centres tested this approach, how a therapy can be labelled “fast-tracked” yet still stay out of patients’ hands, and what he believes keeps an injectable option stuck in limbo.

Then we slow down and get practical. Mike explains the proposed mechanism of action: priming innate immunity, including NK cells, so the immune system can better recognise and attack tumour targets. We also discuss oral versus injectable beta-glucan, daily immune support dosing, the idea of trained immunity, and the add-on protocol he uses for late-stage cancer cases, including ivermectin, fenbendazole, vitamin E, curcumin, and CBD oil tincture depending on the situation. Finally, we cover where he tells people to get the 1-3/1-6 beta-glucan product and what to avoid when shopping.

If this conversation raises new questions for you about cancer treatment, immune support supplements, and the realities of drug approval, share it with someone who needs hope and options, then subscribe and leave a review so more people can find the show.

https://www.jacksonfamilyministry.com

https://bobslone.com/home/podcast-production/